/
Poisoning   Continue on selected drug poisoning Poisoning   Continue on selected drug poisoning

Poisoning Continue on selected drug poisoning - PowerPoint Presentation

kylie
kylie . @kylie
Follow
343 views
Uploaded On 2022-06-18

Poisoning Continue on selected drug poisoning - PPT Presentation

Iron lead Iron Historically iron was a common cause of childhood poisoning deaths The severity of an exposure is related to the amount of elemental iron ingested Ferrous sulfate contains 20 elemental iron ferrous gluconate 12 and ferrous fumarate 33 ID: 920904

iron lead bll children lead iron children bll poisoning blood symptoms chelation ingestion clinical exposure treatment blls edta toxicity

Share:

Link:

Embed:

Download Presentation from below link

Download Presentation The PPT/PDF document "Poisoning Continue on selected drug po..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.


Presentation Transcript

Slide1

Poisoning

Continue on selected drug poisoning

Iron

lead

Slide2

Iron

Historically, iron was a common cause of childhood poisoning deaths. The severity of an exposure is related to the amount of

elemental iron

ingested. Ferrous sulfate contains 20% elemental iron, ferrous gluconate 12%, and ferrous fumarate 33

%.

Slide3

Pathophysiology

Iron is directly corrosive to the GI mucosa, leading to hematemesis, melena, ulceration, infarction, and potential perforation.

Early iron-induced hypotension

is due to massive volume losses, increased permeability of capillary membranes, and

venodilation

mediated by free iron.

Iron accumulates in tissues, including the

Kupffer

cells of the liver and myocardial cells, leading to hepatotoxicity, coagulopathy, and cardiac dysfunction

Slide4

Pediatric patients who ingest >40 mg/kg of elemental iron should be referred to medical care for evaluation, though moderate to severe toxicity is typically seen with ingestions of >60 mg/kg.

Clinical and Laboratory Manifestations:

Iron toxicity is classically described in 4, often overlapping, stages

The initial stage

, 30 min to 6 hr after ingestion, consists of profuse vomiting and diarrhea (often bloody), abdominal pain, and significant volume losses leading to potential

hypovolemic

shock.

Slide5

The second stage, 6 to 24 hr

after ingestion, is the quiescent phase, as GI symptoms typically resolve. careful clinical exam can reveal subtle signs of

hypoperfusion

, including tachycardia, pallor, and fatigue

Slide6

During the third stage, occurring 12 to 24 hr after ingestion, patients develop multisystem organ failure, shock, hepatic and cardiac

dysfunction.

the

fourth stage

(4 to 6 wk after ingestion) is marked by formation of strictures and signs of GI obstruction.

Symptomatic patients and patients with a large exposure by history should have serum iron levels drawn 4-6 hr after ingestion.

Other lab.

Invstigations

….

blood gas, complete blood count, serum glucose level, liver function tests, and coagulation parameters

An abdominal x-ray might reveal the presence of iron tablets.

Slide7

Treatment Close clinical monitoring, combined with aggressive supportive and symptomatic care, is essential to the management of iron poisoning.

Activated charcoal does not adsorb iron, and WBI remains the decontamination strategy of choice.

Deferoxamine, a specific

chelator

of iron, is the antidote for moderate to severe iron intoxication.

Indications for deferoxamine treatment

include a serum iron concentration of >500 mg/

dL

or moderate to severe symptoms of toxicity, regardless of serum iron concentration.

Slide8

Deferoxamine is preferably given via continuous IV infusion at a rate of 15 mg/kg/hr.

Hypotension is a common side effect of

deferoxamine

infusion. Prolonged

deferoxamine infusion (>24 hr) has been associated with pulmonary toxicity (acute respiratory distress syndrome) and

Yersinia

sepsis.

The deferoxamine-iron complex can color the urine reddish (“

vin

ros

?”), though this is an unreliable indicator of iron excretion, therapy is typically continued until clinical symptoms resolve.

Slide9

Lead Poisoning

Lead is a metal that exists in four isotopic forms. Clinically, it is purely a toxicant; no organism has an essential function that is lead-dependent.. The blood lead level (BLL) is the gold standard for determining health effects.

BLL of

5

 

microg

/

dL

???

or greater regarded as a level of concern for public health purposes.

Slide10

Sources of Exposure

Several hundred products contain lead, including batteries, cable sheathing, cosmetics, mineral supplements, plastics,

toys,lead

-based paint. As paint deteriorates, it chalks, flakes, and turns to dust .The dust can coat all surfaces, including children's hands. All of these forms of lead can be ingested.

Slide11

 SOURCES OF LEADPaint chips

Dust

Soil

Parent's or older child's occupational exposure

(painting

)

Home

remedies, including antiperspirants

Stored battery casings (or living near a battery smelter)

Lead-based gasoline

Lead-based

cosmetics (kohl)

Imported

foods in lead-containing cans

Imported toys

Home renovations

Antique toys or furniture

Slide12

Metabolism

The nonnutritive hand-to-mouth activity of young children is the most common pathway by which lead enters the body. In nearly all cases, lead is ingested.

After absorption, lead is disseminated throughout the body. Most retained lead accumulates in bone, where it may reside for years. It circulates bound to erythrocytes; about 97% in blood is bound on or in the red blood

cells.

Slide13

Lead has multiple effects in cells………

It binds to enzymes

, particularly those with available

sulfhydryl

groups, changing the contour and diminishing function.

The

heme

pathway, present in all cells, has three enzymes susceptible to lead inhibitory effects.

The last enzyme in this pathway,

ferrochelatase

, enables

protoporphyrin

to

chelate

iron, thus forming

heme

.

Protoporphyrin

is readily measurable in red blood cells. Levels of

protoporphyrin

higher than 35 

microg

/

dL

are abnormal and are consistent with lead poisoning, iron deficiency, or recent inflammatory disease.

Slide14

A second mechanism of lead toxicity works via its competition with calcium. Many calcium-binding proteins have a higher affinity for lead than for

calcium.

a third mechanism

prevents the development of the normal tertiary brain structure.

Clinical

Effects

The BLL is the best-studied measure of the lead burden in children.

Slide15

Hearing and height are inversely related to BLLs in children;. Children with higher BLLs are slightly shorter than those with lower levels; for every 10

microg

increase in the BLL, the children are 1 cm shorter. Chronic lead exposure also may delay puberty.

there is agreement that

BLLs are

inversely related to cognitive test scores. Because the BLLs from early childhood are predictors of the cognitive test results performed years later, this finding implies that the effects of lead can be permanent.

Slide16

The effect of in utero lead exposure is less clear maternal blood lead levels between 0 and 10microg/

dL

even as early as the first trimester were associated with about a 6-point drop in cognitive test score results when the children were tested up to age 10 yr.

Behavior also is adversely affected by lead exposure. Hyperactivity is noted in young school-aged children with histories of lead poisoning or with concurrent elevations in BLL.

Slide17

Clinical Symptoms

Gastrointestinal Tract and Central Nervous System

GI symptoms

of lead poisoning include anorexia, abdominal pain, vomiting, and constipation, often occurring and recurring over a period of weeks.

CNS symptoms

are related to worsening cerebral edema and increased intracranial pressure. Headaches, change in mentation, lethargy, papilledema, seizures, and coma leading to death are rarely seen at levels lower than 100 

microg

/

dL

but have been reported in children with a BLL as low as 70 

microg

/

dL

.

Slide18

At high levels (>100 microg/

dL

),

renal tubular dysfunction

is observed. Lead may induce a reversible

Fanconi

syndrome.

at high BLLs,

red blood cell survival

is shortened, possibly contributing to a hemolytic anemia, although most cases of anemia in lead-poisoned children are due to other factors, such as iron deficiency and

hemoglobinopathies

.

Older patients may develop a

peripheral neuropathy.

Slide19

Diagnosis

Screening

It is estimated that 99% of lead-poisoned children are identified by screening procedures rather than through clinical recognition of lead-related

symptoms

In general, it is advisable to screen high-risk children, including those with the following characteristics:

1.Having a sibling or playmate with an elevated lead level

2.Living with an adult whose job or hobby involves lead

3.Living near an industry that is likely to release lead (e.g., smelting plant, battery-recycling plant

4. the child is a recent immigrant from a country that still permits use of leaded gasoline

5.or the child has pica or developmental delay

Slide20

NOT RECOMMENDED AT ANY BLOOD LEAD CONCENTRATIONSearching for gingival lead linesEvaluation of renal function (except during chelation with CaNa

2

EDTA [

ethylenediaminetetraacetic

acid])

Testing of hair, teeth, or fingernails for lead

Radiographic imaging of long bones

X-ray fluorescence of long bones

Slide21

Other Tools for Assessment BLL determinations remain the gold standard for evaluating children.

Experimentally, the method of

x-ray fluorescence (XRF) allows direct and noninvasive assessment of bone lead stores.

the

lead mobilization test

.

Lead in hair also is measurable but has problems of contamination and interpretability.

Radiographs of long bones

may show dense bands at the

metaphyses

.

Slide22

For children with acute symptoms,, a kidneys-ureters-bladder (

KUB) radiograph may reveal

radiopaque

flecks

in the intestinal tract, a finding that is consistent with recent ingestion of lead-containing plaster or paint chips.

An

elevated EP value

that cannot be attributed to iron deficiency or recent inflammatory illness

is both an indicator of lead effect and a useful means of assessing the success of the treatment

.

Slide23

Treatment Once lead is in bone, it is released only slowly and is difficult to remove even with chelating agents. Because the cognitive/behavioral effects of lead may be irreversible,

the main effort in treating lead poisoning

is to

prevent

it from occurring and to

prevent

further ingestion by already-poisoned children.

(

1) identification and elimination of environmental sources of lead exposure,

(2) behavioral modification to reduce nonnutritive hand-to-mouth activity, and

(3) dietary counseling to ensure sufficient intake of the essential elements calcium and iron.

Slide24

(4)For the small minority of children with more severe lead poisoning, drug treatment is available that enhances lead excretion.Parental efforts at

reducing the hand-to-mouth activity

of the affected child are necessary to reduce the risk of lead ingestion,

handwashing

is best limited to the period immediately before nutritive hand-to-mouth activity occurs.

Because there is competition between lead and essential minerals, it is reasonable to promote a healthy diet that is sufficient in calcium and iron.

In general, for children 1 yr of age and up a calcium intake of about 1 g per day is sufficient

Slide25

Iron requirements also vary with age, ranging from 6 mg/day for infants to 12 mg/day for adolescents.

Drug treatment

to remove lead is lifesaving for children with lead encephalopathy. In

nonencephalopathic

children, it prevents symptom progression and further toxicity.

Four drugs are available :

2,3-dimercaptosuccinic acid (DMSA [

succimer

])

CaNa

2

EDTA (

versenate

)

penicillamine

British

antilewisite

(BAL [

dimercaprol

]),

DMSA and

penicillamine

can be given orally, whereas CaNa

2

EDTA and BAL can be administered only

parenterally

.

Slide26

<25 μ

g/

dL

Chelation is not indicated.

25-45 μ

g/

dL

Chelation is not routinely indicated because no evidence exists that chelation prevents or reverses neurotoxicity. Some patients may benefit from (oral) chelation (e.g.,

succimer

), especially if elevated levels persist despite aggressive environmental intervention and abatement

45-70 μ

g/

dL

Chelation is indicated with either

succimer

or CaNa

2

EDTA (if no clinical symptoms suggestive of encephalopathy are present [e.g., headache, persistent vomiting]). If symptoms of encephalopathy are seen, chelation With

dimercaprol

and CaNa

2

EDTA are indicated. Before chelation, an abdominal radiograph scan should be taken to evaluate for the possible removable of

enteral

lead.

>70 μ

g/

dL

Inpatient chelation therapy with

dimercaprol

and CaNa

2

EDTA is indicated.

Slide27

NAME

SYNONYM

DOSE

TOXICITY

Succimer

Chemet

, 2,3-dimercaptosuccinic acid (DMSA)

350 mg/m

2

body surface area/dose (

not 10 mg/kg

) q8h, PO for 5 days, then q12h for 14 days

Gastrointestinal distress, rashes; elevated LFTs, depressed white blood cell count

Edetate

CaNa

2

EDTA (calcium disodium edetate), versenate

1,000-1,500 mg/m

2

body surface area/d; IV infusion—continuous or intermittent; IM divided q6h or q12h for 5 days

Proteinuria

,

pyuria

, rising blood urea nitrogen/

creatinine

—all rare

Hypercalcemia

if too rapid an infusion

Tissue inflammation if infusion infiltrates

Slide28

British

antilewisite

(BAL)

Dimercaprol, British antilewisite

300-500 mg/m

2

body surface area/ day;

IM only

divided q4h for 3-5 days. Only for BLL ≥ 70 ?g/dL

GI distress, altered

mentation

; elevated LFTs, hemolysis if glucose-6-phosphate

dehydrogenase

deficiency; no concomitant iron treatment

D-Pen

Penicillamine

10 mg/kg/d for 2 wk increasing to 25-40 mg/kg/d; oral, divided q12h.

For 12-20 wk

Rashes, fever; blood

dyscrasias

, elevated LFTs,

proteinuria

Allergic cross-reactivity with penicillin

Slide29

All of the drugs are effective in reducing BLLs when given in sufficient doses and for the prescribed time. These drugs also may increase lead absorption from the gut and should be administered to children in lead-free environments.

None of these agents removes all lead from the body. Within days to weeks after completion of a course of therapy the BLL rises, even in the absence of new lead ingestion. The source of this rebound in the BLL is believed to be bone.

With successful intervention, BLLs decline, with the greatest fall in BLL occurring in the first 2 mo after therapy is initiated. Subsequently the rate of change in BLL declines slowly so that by 6-12 mo after identification, the BLL of the average child with moderate lead poisoning (BLL >20 

microg

/

dL

) will be 50% lower.

Slide30

Early screening remains the best way of avoiding and therefore obviating the need for the treatment of lead poisoning.